Compare Duke Energy Corp (DUK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs BIO-TECHNE Corp — how do they compare? Duke Energy Corp trades at $123.08 (market cap $94.49B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: Duke Energy Corp is far larger — about 8.4× BIO-TECHNE Corp's market cap, and Duke Energy Corp pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| DUK | TECH | |
|---|---|---|
Market Cap | $94.49B | $11.24B |
Sector | Utilities | Health |
52-Week High | $133.46 | $72.29 |
52-Week Low | $113.99 | $43.31 |
Enterprise Value | $187.00B | $11.32B |
Dividend Yield | 3.58% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $124.85, up 0.77% in the last session, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $1.43, exceeding the $1.30 estimate, and maintains strong profitability with a net margin of 15.78%. Revenue growth is steady, reaching $32.24B in 2025, while analyst consensus is a Buy with a $136.17 price target. Recent news highlights equity offerings and regulatory agreements impacting capital plans.
The outlook for DUK is cautiously optimistic, supported by consistent earnings performance and dividend payments, but weighed by high debt levels and bearish technical indicators. Investment appeal lies in its stable utility model and growth in power demand, though risks include regulatory scrutiny and interest rate sensitivity. The stock offers value near current levels with upside to analyst targets.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
